-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Medline, Raises Price Target to $45

Benzinga·11/20/2026 15:14:38
Listen to the news
Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and raises the price target from $43 to $45.